Business
BullFrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners
First commercial agreement with a top 5 global pharmaceutical company anchors a growing pipeline of enterprise discussions; runway secured into late 2027
About this update from Bullfrog Ai Holdings, Inc.
[{"type":"text","content":"First commercial agreement with a top 5 global pharmaceutical company anchors a growing pipeline of enterprise discussions; runway secured into late 2027\nGAITHERSBURG, Md., April 13, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (Nasdaq: BFRG; BFRGW) (\"BullFrog AI\" or the \"Company\"), a technology company using artificial intelligence and machine learning to turn complex biomedical data into actionable insights, today issued the following letter to shareholders from Vin Singh, Founder and CEO: Dear Fellow Shareholders, BullFrog AI enters the second quarter of 2026 well-capitalized, at commercial stage, and in active discussions with consequential pharmaceutical and biotechnology organizations. We just closed our first agreement with a top 5 global pharmaceutical company, secured the financial runway to execute our strategy into late 2027, and are deeply engaged with an industry that is no longer evaluating whether to embrace AI-driven drug discovery — but deciding with whom. The transformation of pharmaceutical R&D through artificial intelligence is no longer a thesis — it is a market reality being priced in real time. In particular, news of Anthropic's reported $400 million acquisition of a pre-commercial stage AI drug discovery startup sent an unambiguous signal about the value sophisticated capital is now placing on purpose-built, biology-native AI platforms. This transaction, among others, points to an industry that is currently focused on exploring and pursuing artificial intelligence solutions to power and advance their R&D programs. A CRITICAL COMMERCIAL AGREEMENT — AND THE FOUNDATION THAT EARNED IT On March 30, 2026, we announced a commercial feasibility agreement with a top 5 global pharmaceutical company by 2025 revenue. Under the agreement, our proprietary bfLEAP® platform will identify and prioritize novel drug targets in major depressive disorder — a market valued at more than $8 billion in 2025 and projected to exceed $11 billion by 2032. The agreement includes milestone payments tied to defined deliverables and provides our partner with an option to secure exclusive rights to a final selected target candidate for research and development purposes. This milestone agreement did not emerge in isolation. BullFrog AI's technology is derived from research originally conducted at the Johns Hopkins University Ap...